Please login to the form below

Not currently logged in
Email:
Password:

Age-related macular degeneration

This page shows the latest Age-related macular degeneration news and features for those working in and with pharma, biotech and healthcare.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis.

Latest news

More from news
Approximately 1 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    for advanced dry Age-related Macular Degeneration (AMD). ... She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust

  • Deal Watch October 2018

    RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    treatments for age-related macular degeneration (AMD).

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD). ... Despite the uncertainty and challenges in our environment, particularly related to Brexit, we need

  • Deal Watch February 2016 Deal Watch February 2016

    company. Avalanche's preclinical and research stage gene therapy programmes are focused on a range of ophthalmic diseases, such as wet age-related macular degeneration, utilising adeno-associated virus (AAV) vectors. ... Onxeo is paying around $1.85m

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Biotech: it's a people business

    From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of ... Because of my mother, I was on the other side

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics